Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center)
Clinical Cancer Research
January 10, 2025
10.1158/1078-0432.ccr-24-2920
Cited by 41

Related Papers

No related papers found

Powered by citation graph analysis